NZ597857A - Method and composition for treating mucosal disorders - Google Patents

Method and composition for treating mucosal disorders

Info

Publication number
NZ597857A
NZ597857A NZ597857A NZ59785706A NZ597857A NZ 597857 A NZ597857 A NZ 597857A NZ 597857 A NZ597857 A NZ 597857A NZ 59785706 A NZ59785706 A NZ 59785706A NZ 597857 A NZ597857 A NZ 597857A
Authority
NZ
New Zealand
Prior art keywords
composition
treating mucosal
mucosal disorders
disorders
treating
Prior art date
Application number
NZ597857A
Other languages
English (en)
Inventor
Ryuji Ueno
Sachiko Kuno
Anthony T Blikslager
Adam J Moeser
Original Assignee
Univ North Carolina State
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State, Sucampo Ag filed Critical Univ North Carolina State
Publication of NZ597857A publication Critical patent/NZ597857A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ597857A 2005-03-21 2006-03-22 Method and composition for treating mucosal disorders NZ597857A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66320005P 2005-03-21 2005-03-21
US67992005P 2005-05-11 2005-05-11
US72197605P 2005-09-30 2005-09-30
NZ588878A NZ588878A (en) 2005-03-21 2006-03-22 Method and composition for treating cancer using a prostaglandin such as lubiprostone

Publications (1)

Publication Number Publication Date
NZ597857A true NZ597857A (en) 2013-08-30

Family

ID=36754577

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ597857A NZ597857A (en) 2005-03-21 2006-03-22 Method and composition for treating mucosal disorders
NZ588878A NZ588878A (en) 2005-03-21 2006-03-22 Method and composition for treating cancer using a prostaglandin such as lubiprostone
NZ562351A NZ562351A (en) 2005-03-21 2006-03-22 Method and composition for treating mucosal disorders using a prostaglandin such as lubiprostone

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ588878A NZ588878A (en) 2005-03-21 2006-03-22 Method and composition for treating cancer using a prostaglandin such as lubiprostone
NZ562351A NZ562351A (en) 2005-03-21 2006-03-22 Method and composition for treating mucosal disorders using a prostaglandin such as lubiprostone

Country Status (14)

Country Link
US (1) US20060281818A1 (enExample)
EP (3) EP2384790A3 (enExample)
JP (2) JP5219797B2 (enExample)
KR (2) KR101456298B1 (enExample)
CN (1) CN103948603A (enExample)
AU (1) AU2006225515B2 (enExample)
BR (1) BRPI0609672A2 (enExample)
CA (2) CA2601158C (enExample)
ES (1) ES2592283T3 (enExample)
IL (1) IL185861A (enExample)
MX (1) MX2007011645A (enExample)
NO (1) NO20075361L (enExample)
NZ (3) NZ597857A (enExample)
WO (1) WO2006101244A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
CN101918017B (zh) * 2007-10-25 2013-07-31 植物药学公司 Phy906用于治疗炎性肠病和/或肠易激综合征的用途
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
AU2012246999A1 (en) * 2011-04-19 2013-10-17 Sucampo Ag Method for modulating cytokine activity
JP2014515004A (ja) * 2011-04-27 2014-06-26 スキャンポ・アーゲー イオン輸送体の調節方法
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease
EP3292135B1 (en) * 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
WO2024217532A1 (zh) * 2023-04-20 2024-10-24 中南大学湘雅二医院 Carboprost在制备抗肿瘤药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPS58216155A (ja) * 1982-06-10 1983-12-15 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
JPS591463A (ja) * 1982-06-28 1984-01-06 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
FR2608924B1 (fr) * 1986-12-29 1990-07-20 Pasteur Institut Compositions therapeutiques contenant des derives soufres de prostaglandines, nouveaux derives soufres et leur procede de preparation
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) * 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5234858A (en) 1990-11-16 1993-08-10 Micron Technology, Inc. Stacked surrounding wall capacitor
KR940007277B1 (ko) 1992-02-14 1994-08-12 한국과학기술원 2차 전지 전극용 수소 저장 합금
US5376034A (en) 1992-05-27 1994-12-27 Brunswick Corporation Marine drive exhaust system
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
US5876034A (en) 1997-12-17 1999-03-02 Stafford; James R. Sporting fishing board game
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
GB2375349A (en) * 2001-02-13 2002-11-13 Glaxo Group Ltd Chloride intracellular channel-related proteins
US6919082B2 (en) * 2001-02-13 2005-07-19 Kirin Beer Kabushiki Kaisha Pharmacological composition containing yeast cell wall fraction
GB0111497D0 (en) * 2001-05-11 2001-07-04 Medical Res Council Therapeutic methods
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
JP4889219B2 (ja) * 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders

Also Published As

Publication number Publication date
KR20140072102A (ko) 2014-06-12
CA2601158A1 (en) 2006-09-28
EP2384790A2 (en) 2011-11-09
BRPI0609672A2 (pt) 2010-04-20
IL185861A (en) 2015-06-30
EP1861169A2 (en) 2007-12-05
AU2006225515A1 (en) 2006-09-28
AU2006225515A8 (en) 2006-09-28
EP2384791A3 (en) 2011-12-28
KR20080012266A (ko) 2008-02-11
US20060281818A1 (en) 2006-12-14
WO2006101244A2 (en) 2006-09-28
CA2831416C (en) 2016-12-13
EP2384791A2 (en) 2011-11-09
KR101456298B1 (ko) 2014-11-03
CN103948603A (zh) 2014-07-30
AU2006225515B2 (en) 2012-02-02
NZ562351A (en) 2010-12-24
CA2601158C (en) 2015-10-13
IL185861A0 (en) 2008-01-06
JP2012180380A (ja) 2012-09-20
ES2592283T3 (es) 2016-11-29
EP1861169B1 (en) 2016-05-11
JP5219797B2 (ja) 2013-06-26
JP5777574B2 (ja) 2015-09-09
JP2008533195A (ja) 2008-08-21
NO20075361L (no) 2007-12-20
NZ588878A (en) 2012-05-25
CA2831416A1 (en) 2006-09-28
WO2006101244A3 (en) 2007-02-08
EP2384791B1 (en) 2016-06-15
EP2384790A3 (en) 2011-12-28
MX2007011645A (es) 2007-11-16

Similar Documents

Publication Publication Date Title
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
TW200734311A (en) New compounds
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
PL1853588T3 (pl) Związki chemiczne
MX2009007231A (es) Compuestos quimicos 637:piridopirimidindionas como inhibidores de la fosfodiesterasa 4.
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
NO20082096L (no) Azaindol-2-karboksamidderivativer
MX2008010035A (es) Compuestos de n-hidroxiacrilamida.
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
EA201100872A1 (ru) Производные хиназолинамида
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
PT1606288E (pt) Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
PH12012501636A1 (en) 2-((r)-2- methylpyrrolidin -2-yl) -1h- benzimidazole -4- carboxamide crystalline form 1
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 22 MAR 2016 BY HENRY HUGHES

Effective date: 20140303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2017 BY HENRY HUGHES IP LIMITED

Effective date: 20160216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2018 BY HENRY HUGHES IP LIMITED

Effective date: 20170124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190302

LAPS Patent lapsed